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CORRECTION
Correction: The Rationale for Using Rifabutin
in the Treatment of MDR and XDR
Tuberculosis Outbreaks
Frederick A. Sirgel, Robin M. Warren, Erik C. Böttger, Marisa Klopper, Thomas C. Victor,
Paul D. van Helden
There is an error in Table 1. An AspTyr mutation is wrongly abbreviated as D516T (1). It
should be listed as D516Y (1). Please see the corrected Table 1 here.
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Table 1. MICs and relative resistance of rifampicin and rifabutin inM. tuberculosis.
Genotype rpoB Rifampicin Rifabutin
Mutants (n) MIC μg/ml bRR MIC μg/ml RR
Atypical Beijing D516Y (1) 5.0 10 0.125 2
D516S (4) 5.0–15 10–30 0.125–0.25 2–4
D516V (29) 10–15 20–30 0.125–0.25 2–4
Undetermined aWild-type (26) 0.5 - 0.06 -
Typical Beijing S531L (1) >10 >20 >1.0 >16
Atypical Beijing Q510P (1) >10 >20 >1.0 >16
aTwenty-ﬁve clinical isolates with unknown genotype plus one H37Rv strain were included as controls.
bRR indicates relative resistance: Mutant MIC/Wild-type MIC.
doi:10.1371/journal.pone.0134190.t001
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